{"id":"https://openalex.org/W1189025943","doi":null,"title":"Pharmacological properties of the PI3 kinase (PI3K) inhibitors PI-540 and PI-620","display_name":"Pharmacological properties of the PI3 kinase (PI3K) inhibitors PI-540 and PI-620","publication_year":2008,"publication_date":"2008-05-01","ids":{"openalex":"https://openalex.org/W1189025943","mag":"1189025943"},"language":"en","primary_location":{"id":"mag:1189025943","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/68/9_Supplement/LB-149","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058014829","display_name":"Florence I. Raynaud","orcid":"https://orcid.org/0000-0003-0957-6279","observed_orcids":["https://orcid.org/0000-0003-0957-6279"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Florence I. Raynaud","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0003-0957-6279","affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061423488","display_name":"Angela Hayes","orcid":"https://orcid.org/0000-0001-6788-5761","observed_orcids":["https://orcid.org/0000-0001-6788-5761"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Angela Hayes","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-6788-5761","affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101890953","display_name":"Francesca Di Stefano","orcid":"https://orcid.org/0000-0003-4545-2169","observed_orcids":["https://orcid.org/0000-0003-4545-2169"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Francesca Di Stefano","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0003-4545-2169","affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042056024","display_name":"Paul Andrew Clarke","orcid":"https://orcid.org/0000-0001-9342-1290","observed_orcids":["https://orcid.org/0000-0001-9342-1290"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul A. Clarke","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-9342-1290","affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089603827","display_name":"Melanie R. Valenti","orcid":"https://orcid.org/0000-0001-7610-1375","observed_orcids":["https://orcid.org/0000-0001-7610-1375"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Melanie Valenti","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-7610-1375","affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103545247","display_name":"Zahida Ahmad","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Zahida Ahmad","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016775053","display_name":"Sue A. Eccles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sue Eccles","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050781087","display_name":"Adrian J. Folkes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Adrian Folkes","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076385688","display_name":"Nahid Saghir","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nahid Saghir","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057703124","display_name":"Anthony G. Robson","orcid":"https://orcid.org/0000-0002-8391-6123","observed_orcids":["https://orcid.org/0000-0002-8391-6123"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Anthony G. Robson","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-8391-6123","affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108371532","display_name":"Stephen Shuttleworth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen Shuttleworth","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003965204","display_name":"Paul Workman","orcid":"https://orcid.org/0000-0003-1659-3034","observed_orcids":["https://orcid.org/0000-0003-1659-3034"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul Workman","raw_affiliation_strings":["CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0003-1659-3034","affiliations":[{"raw_affiliation_string":"CR UK Centre for Cancer Therapeutics, Sutton, Surrey, United Kingdom, Piramed Pharma, Slough, Berkshire, United Kingdom, Karus Therapeutics Ltd., Southampton, Hampshire, United Kingdom","institution_ids":["https://openalex.org/I2801316944"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I2801316944"],"apc_list":null,"apc_paid":null,"fwci":0.112,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.42875747,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"68","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.9409999847412109},{"id":"https://openalex.org/keywords/thienopyrimidines","display_name":"thienopyrimidines","score":0.8339999914169312},{"id":"https://openalex.org/keywords/pi-103","display_name":"PI-103","score":0.9070000052452087},{"id":"https://openalex.org/keywords/p110alpha","display_name":"p110\u03b1","score":0.7089999914169312},{"id":"https://openalex.org/keywords/p110beta","display_name":"p110\u03b2","score":0.9169999957084656},{"id":"https://openalex.org/keywords/p110delta","display_name":"p110\u03b4","score":0.996999979019165},{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.6940000057220459},{"id":"https://openalex.org/keywords/ovarian-carcinoma","display_name":"ovarian carcinoma","score":0.9340000152587891},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7599999904632568},{"id":"https://openalex.org/keywords/antitumour-efficacy","display_name":"antitumour efficacy","score":0.8029999732971191},{"id":"https://openalex.org/keywords/antiangiogenic-activity","display_name":"antiangiogenic activity","score":0.9229999780654907},{"id":"https://openalex.org/keywords/drug-solubility","display_name":"drug solubility","score":0.8600000143051147},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C53009064","wikidata":"https://www.wikidata.org/wiki/Q167","display_name":"Pi","level":2,"score":0.7413436770439148},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.546185314655304},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5124531388282776},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.49524298310279846},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4577062129974365},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.45359936356544495},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4279240369796753},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42289817333221436},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41161245107650757},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.36877769231796265},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.3391251564025879},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32267314195632935},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23045432567596436},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17708450555801392},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:1189025943","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/68/9_Supplement/LB-149","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2107343029","https://openalex.org/W1436721071","https://openalex.org/W2115484306","https://openalex.org/W1514378709","https://openalex.org/W2516675447","https://openalex.org/W1984777958","https://openalex.org/W1998836974","https://openalex.org/W2232754526","https://openalex.org/W4416050080","https://openalex.org/W3141987310"],"abstract_inverted_index":{"AACR":[0],"Annual":[1],"Meeting--":[2],"Apr":[3],"12-16,":[4],"2008;":[5],"San":[6],"Diego,":[7],"CA\n\nLB-149":[8],"\n\nThe":[9],"PI3K":[10,81,225],"pathway":[11,54,132],"is":[12],"highly":[13],"deregulated":[14],"in":[15,27,67,90,101,134,179,211,214],"cancer":[16,49,231],"and":[17,45,64,84,117,151,165,173,183,193,200,213,241],"has":[18,57],"been":[19],"the":[20,28,35,74,79,123,135,180],"focus":[21],"of":[22,42,78,95,191,224],"much":[23],"drug":[24],"discovery":[25],"effort":[26],"last":[29],"decade.":[30],"We":[31],"have":[32],"previously":[33],"reported":[34],"pyridofuropyrimidine":[36],"PI-103":[37,47,160],"as":[38,61],"a":[39,88,216],"potent":[40],"inhibitor":[41],"p110\u03b1,":[43],"p110\u03b2":[44],"p110\u03b4(1).":[46],"inhibits":[48],"cell":[50,111],"proliferation":[51],"consistent":[52],"with":[53,159,189],"modulation":[55,133],"but":[56],"pharmaceutical":[58],"limitations":[59],"such":[60],"poor":[62],"solubility":[63,155],"significant":[65,176,217],"metabolism":[66],"liver":[68],"microsomal":[69],"incubations.":[70],"Here":[71],"we":[72],"report":[73],"improved":[75,154],"pharmacological":[76],"properties":[77],"thienopyrimidine":[80],"inhibitors.":[82],"PI-540":[83,150,164,172,196],"PI-620":[85,152,174,201],"that":[86,94],"show":[87],"similar":[89,131],"vitro":[91,212],"profile":[92],"to":[93,168,208],"PI-103.":[96,171],"Submicromolar":[97],"efficacy":[98,178],"was":[99,220,235],"observed":[100],"U87MG":[102,181],"glioblastoma":[103,125,182],"cells,":[104],"PC3":[105],"prostate":[106],"carcinoma,":[107],"Detroit":[108],"562":[109],"squamous":[110],"carcinoma":[112,116,186],",":[113],"IGROV-1":[114],"ovarian":[115,185],"human":[118,124],"endothelial":[119],"cells":[120],"(HUVEC).":[121],"In":[122,206],"U87MG,":[126],"all":[127],"3":[128],"compounds":[129],"showed":[130,153,175],"multiplexed":[136],"electroluminescent":[137],"immunoassay":[138],"(Mesoscale":[139],"Discovery;":[140],"see":[141],"Table).":[142],"(>100\u03bcM)":[156],"when":[157],"compared":[158,167],"(":[161],"30":[162],"for":[163,170,195,230],"PI-620;":[166],"1":[169],"antitumour":[177],"SKOV3":[184],"xenograft":[187],"models":[188],"T/C":[190],"66":[192],"60":[194],"at":[197,202],"100mg/kg":[198],"uid":[199],"25mg/kg":[203],"bid":[204],"respectively.":[205],"addition":[207],"growth":[209],"inhibition":[210],"vivo,":[215],"antiangiogenic":[218],"effect":[219],"observed.":[221],"This":[222,233],"series":[223],"inhibitors":[226],"shows":[227],"considerable":[228],"potential":[229],"treatment.":[232],"work":[234],"funded":[236],"by":[237,242],"Cancer":[238,252],"Research":[239,253],"UK":[240],"Piramed":[243],"Ltd.":[244],"1.":[248],"Raynaud":[249],"et":[250],"al.,":[251],"67;12:5840,":[254],"2007.\n\nView":[255],"this":[256],"table:":[257]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}